Background: This study investigates the value of fluorine 18 ([F])-labeled fibroblast activation protein inhibitor (FAPI) for lymph node (LN) metastases in patients with stage I-IIIA non-small cell lung cancer (NSCLC).
Methods: From November 2021 to October 2022, 53 patients with stage I-IIIA NSCLC who underwent radical resection were prospectively included. [F]-fluorodeoxyglucose (FDG) and [F]FAPI examinations were performed within one week. LN staging was validated using surgical and pathological findings. [F]FDG and [F]FAPI uptake was compared using the Wilcoxon signed-ranks test. Furthermore, the diagnostic value of nodal groups was investigated.
Results: In 53 patients (median age, 64 years, range: 31-76 years), the specificity of [F]FAPI for detecting LN metastasis was significantly higher than that of [F]FDG (P < 0.001). High LN risk category, greater LN short-axis dimension(≥ 1.0 cm), absence of LN calcification or high-attenuation, and higher LN FDG SUV (≥ 10.1) were risk factors for LN metastasis(P < 0.05). The concurrence of these four risk factors accurately predicted LN metastases (Positive Predictive Value [PPV] 100%), whereas the presence of one to three risk factors was unable to accurately discriminate the nature of LNs (PPV 21.7%). Adding [F]FAPI in this circumstance improved the diagnostic value. LNs with an [F]FAPI SUV<6.2 were diagnosed as benign (Negative Predictive Value 93.8%), and LNs with an [F]FAPI SUV≥6.2 without calcification or high-attenuation were diagnosed as LN metastasis (PPV 87.5%). Ultimately, the integration of [F]FDG and [F]FAPI PET/CT resulted in the highest accuracy for N stage (83.0%) and clinical decision revisions for 29 patients.
Conclusion: In patients with stage I-IIIA NSCLC, [F]FAPI contributed additional valuable information to reduce LN diagnostic uncertainties after [F]FDG PET/CT. Integrating [F]FDG and [F]FAPI PET/CT resulted in more precise clinical decisions.
Trial Registration: The Chinese Clinical Trial Registry: ChiCTR2100044944 (Registered: 1 April 2021, https://www.chictr.org.cn/showprojEN.html?proj=123995 ).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145785 | PMC |
| http://dx.doi.org/10.1186/s40644-024-00701-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma.
JTCVS Open
December 2024
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Objective: To identify clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma (LUAD) and to evaluate survival after brain metastasis.
Methods: Patients who underwent complete resection of stage I-IIIA LUAD between 2011 and 2020 were included. A subset of patients had broad-based panel next-generation sequencing performed on their tumors.
Recurrence Risk and Its Impact on Current Treatment Strategies in Early and Locally Advanced NSCLC.
Anticancer Res
December 2024
Respiratory Division, Department of Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Background/aim: Recurrence rates in early and locally advanced non-small-cell lung cancer (NSCLC) remain high despite curative treatment. Recently, the survival benefit of immune checkpoint inhibitors (ICI) in the (neo)adjuvant setting in patients with stage II-III NSCLC has been demonstrated. This study aimed to identify predisposing factors for disease recurrence to select patients who would benefit from multimodality treatment.
View Article and Find Full Text PDFSurgical treatment of thymic epithelial tumor and myasthenia gravis.
Front Surg
November 2024
Department of Thoracic Surgery, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Türkiye.
Article Synopsis
- * Thymomas grow slowly and are localized, while thymic carcinomas grow quickly and can spread, with respective 5-year survival rates of 78% and 30%.
- * Treatment depends on tumor resectability, starting with surgery for early-stage cases, followed by chemotherapy for more advanced stages, while conditions like myasthenia gravis are associated with these tumors and can be treated through various methods, including extended thymectomy.
Pre-operative carcino-embryonic antigen prognosticates early disease-free survival following curative surgery for non-small cell lung cancer.
Med J Malaysia
November 2024
Sunway Medical Centre, Sunway Clinical Research Centre, Sunway City, Selangor, Malaysia.
Article Synopsis
- Serum carcinoembryonic antigen (CEA) is indicated as a valuable prognostic biomarker for recurrence and survival in patients with early non-small cell lung cancer (NSCLC) after curative surgery.
- The study involved 18 patients with early-stage NSCLC, measuring their serum CEA levels before and after surgical resection over a follow-up period, revealing that 39% had elevated pre-operative CEA levels.
- Results showed that patients with a baseline CEA level above 5.0 ng/ml had significantly poorer disease-free survival compared to those with lower levels, underlining the potential of CEA to identify patients at risk for worse outcomes.
Two-Year Experience of a Center of Excellence for the Comprehensive Management of Non-Small Cell Lung Cancer at a Fourth-Level Hospital in Bogota, Colombia: Observational Case Series Study and Retrospective Analysis.
J Clin Med
November 2024
Fundación Santa Fe de Bogotá Centro de Cuidado Clínico de Cáncer de Pulmón, Bogotá 110111, Colombia.
This study aimed to provide a comprehensive analysis of 56 patients admitted to the Lung Cancer Clinical Care Center (C3) at Fundación Santa Fe de Bogotá (FSFB) between 2 May 2022 and 22 April 2024. The focus was on demographic characteristics, smoking history, comorbidities, lung cancer types, TNM classification, treatment modalities, and outcomes. This observational case series study reviewed medical records and included patients over 18 years with a confirmed diagnosis of non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!